Existing treatments for gout and hyperuricemia are not always effective in lowering the uric acid to target level to control gout or prevent uric acid from accumulating in the body; these drugs also are often associated with a series of adverse effects that can, in some cases be fatal.

Shanton Pharma’s lead program SAP-001 works through a unique combination of pathways to regulate over production and increase excretion of uric acid to effectively reduce serum uric acid levels.